Prevention is better than cure

The Lancet

Volumn 375, Issue 9713, 2010, Pages 513-523

  Borysiewicz, Leszek K ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BCG VACCINE; CANCER VACCINE; ISONIAZID; MEASLES MUMPS RUBELLA VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SMALLPOX VACCINE;

ANTIVIRAL THERAPY; ARTICLE; DISEASE TRANSMISSION; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GEOGRAPHIC DISTRIBUTION; HEALTH CARE DELIVERY; HEALTH CARE DISTRIBUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEASLES; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; MUMPS; PRIORITY JOURNAL; RUBELLA; SMALLPOX; TUBERCULOSIS; UTERINE CERVIX CANCER; VACCINATION; WORLD HEALTH ORGANIZATION;

EID: 75749120959     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61757-8     Document Type: Note

References (80)

1. Jenner E. An Inquiry into the causes and effects of Variolae Vaccinae, a disease discovered in some of the Western Counties of England, particularly Gloucestershire and known by the name of The Cow Pox. 1st edn (1798), Sampson Low, London
2. Cartwright F.F. A social history of medicine. 1st edn (1977), Longman, London
3. Williamson S. The vaccination controversy-the rise, reign and fall of compulsory vaccination for smallpox. 1st edn (2007), Liverpool University Press, Liverpool
4. Creighton C. A history of epidemics in Britain - II from the extinction of plague to the present time. 1st edn (1894), Cambridge University Press, Cambridge
5. Creighton C. Jenner and vaccination-a strange chapter of medical history. 1st edn (1889), Swan Sonnerscein & Co, London
6. Quain R. The Harveian Oration on the history and progress of medicine. BMJ 2 (1885) 775-781
7. Fenner F., Henderson D., Arita I., Jezek Z., and Ladnyi I. Smallpox and its eradication. 1st edn (1988), World Health Organization, Geneva
8. Strassburg M. The global eradication of smallpox. N Engl J Med 303 (1980) 1263-1273
9. WHO. Progress towards interrupting wild poliovirus transmission worldwide, 2008. Wkly Epidemiol Rec 84 (2009) 110-116
10. Elliman D., and Bedford H. MMR: where are we now?. Arch Dis Child 92 (2007) 1055-1057
11. Thompson G. Measles and MMR Statistics. House of Commons Standard Note (2008), House of Commons Report number SN/SG/2581.
12. Peltola H., Jokinen S., Paunia M., Hovi T., and Davidkin I. Measles, mumps and rubella in Finland: 25 years of a nationwide elimination programme. Lancet Infect Dis 8 (2008) 796-803
13. Casiday R., Cresswell T., Wilson D., and Panter-Brick C. A survey of UK parental attitudes to the MMR vaccine and trust in medical authority. Vaccine 24 (2006) 177-184
14. Whipple T. Newspapers must shut up about MMR. The Times (London) (June 22, 2009). http://www.timesonline.co.uk/tol/life_and_style/health/child_health/article6549259.ece (accessed Dec 22, 2009).
15. Hargreaves I., Lewis J., and Speers T. Towards a better map: science, the public and the media (2003), ESRC, Swindon 1-64
16. Murray J. A century of tuberculosis. Am J Respir Crit Care Med 169 (2004) 1181-1186
17. Fishberg M. Pulmonary tuberculosis. 2nd edn (1919), Lea and Febiger, Philadelphia
18. Hoft D. Tuberculosis vaccine development: goals, immunological design, and evaluation. Lancet 372 (2008) 164-175
19. Daniel T. The history of tuberculosis. Respir Med 100 (2006) 1862-1870
20. Mitchison D. The diagnosis and therapy of tuberculosis during the past 100 years. Am J Respir Crit Care Med 171 (2005) 699-706
21. Young D., Perkins M., Duncan K., and Barry C. Confronting the scientific obstacles to global control of tuberculosis. J Clin Invest 118 (2008) 1255-1265
22. Colditz G., Berkey C., Mosteller F., et al. The efficacy of Bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 96 (1995) 29-35
23. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. BMJ 2 (1948) 769-782
24. Fox W., Ellard G., and Mitchison D. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units 1946-1986. Int J Tuberc Lung Dis 3 suppl 2 (1999) S231-S279
25. WHO. Global tuberculosis comtrol 2008: surveillance, planning and financing (2008), World Health Organization, Geneva Report number WHO/HTM/TB/2008.393.
26. Shenoi S., Heysell S., Moll A., and Friedland G. Multi-drug-resistant and extensively drug-resistant tuberculosis: consequences for the global HIV community. Curr Opin Infect Dis 22 (2009) 11-17
27. Nguyen L., and Pieters J. Mycobacterial subversion of chemotherapeutic reagents and host defence tactics: challenges in tuberculosis drug development. Ann Rev Pharmacol Toxicol 49 (2009) 427-453
28. WHO. Anti-tuberculosis drug resistance in the world; 4th report (2008), World Health Organisation, Geneva Report number WHO/HTM/TB/2008.394.
29. Wright A., Zignol M., Van Deun A., et al., for the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 373 (2009) 1861-1873
30. Jassal M., and Bishai W. Extensively drug-resistant tuberculosis. Lancet Infect Dis 9 (2009) 19-30
31. LoBue P. Extensively drug-reisitant tuberculosis. Curr Opin Infect Dis 22 (2009) 167-173
32. Andrews J.R., Gandhi N.R., Moodley P., et al., Tugela Ferry Care and Research Collaboration. Exogenous reinfection as a cause of multidrug-resistant and extensively drug-resistant tuberculosis in rural South Africa. J Infect Dis 198 (2008) 1582-1589
33. Horsborough Jr. C. Primary transmission of multidrug-resistant and extensively drug-resistant tuberculosis among HIV-infected persons: what does the future hold in store. J Infect Dis 198 (2008) 1577-1578
34. Zhao M., Li X., Xu P., et al. Transmission of MDR and XDR tuberculosis in Shanghai, China. PLoS ONE 4 (2009) e4370
35. Nyendak M., Lewinsohn D., and Lewinsohn D. New diagnostic methods for tuberculosis. Curr Opin Infect Dis 22 (2009) 174-182
36. Orenstein E., Basu S., Shah N., et al. Treatment outcomes among aptients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 9 (2009) 153-161
37. Pacific Health Summit. Multidrug-resistant tuberculosis (MDR-TB) (2009), The National Bureau of Asian Research, Seattle
38. Rieder H. Fourth-generation fluroquinolones in tuberculaosis. Lancet 373 (2009) 1148-1149
39. Barry C. Unorthodox approach to the development of new antituberculous therapy. N Engl J Med 360 (2009) 2466-2467
40. Rawlins M. De testemonio: on the evidence for decisions about the use of therapeutic interventions. Lancet 372 (2008) 2152-2161
41. Dart Trial Team. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trials. Lancet (2009) 10.1016/S0140-6736(09)62067-5 published online Dec 9.
42. Inskip H., Hall A., Chotard J., Loik F., and Whittle H. Hepatitis B vaccine in the Gambian expanded programme on immunization: factors influencing antibody response. Int J Epidemiol 20 (1991) 764-769
43. Whittle H., Jaffar S., Wansbrough M., et al. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ 325 (2002) 569-574
44. Beasley R. Rocks along the road to the control of HBV and HCC. Ann Epidemiol 19 (2009) 231-234
45. Kogevinas M., Pearce N., Susser M., and Boffetta P. Social inequalities and cancer (1997), IARC, Lyon
46. Benard V., Johnson C., and Thompson T. Examining the association between socioeconomic status and potential human papillomavirus-associated cancers. Cancer 113 suppl 10 (2008) 2910-2918
47. Ronco G., Arbyn M., and Segnan N. Cervical screening according to age and HPV status. BMJ 339 (2009) 306-307
48. zur Hausen H. Nobel Lecture: the search for infectious causes of human cancers: where and why? (2008). http://nobelprize.org/nobel_prizes/medicine/laureates/2008/hausen-lecture.html (accessed Oct 1, 2009).
49. Munoz N., Bosch F.X., de Sanjose S., et al., for the IARC Multicentre Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 (2003) 518-527
50. Koutsky L., Holmes K., Critchlow C., et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 327 (1992) 1272-1278
51. International Agency for Research on Cancer. Human papillomaviruses: mongraphs on the evaluation of carcinogenic risks to humans (1995), World Health Organisiation, Lyon
52. Stanley M. Genital human papillomavirus infections-current and prospective therapies. J Natl Cancer Inst Monogr 31 (2003) 117-124
53. Stanley M. HPV vaccines: are they the answer?. Br Med Bull 88 (2008) 59-74
54. Borysiewicz L., Fiander A., Nimako M., et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347 (1996) 1523-1527
55. Nimako M., Fiander A., Wilkinson G., Borysiewicz L., and Man S. Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III. Cancer Res 57 (1997) 4855-4861
56. Evans E., Man S., Evans A., and Borysiewicz L. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. Cancer Res 57 (1997) 2943-2950
57. Mehta A., Jordanova E., Kenter G., Ferrone S., and Fleuren G.J. Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother 57 (2008) 197-206
58. Zhou J., Sun X., Stenzel D., and Frazer I. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virus-like partcles. Virology 185 (1991) 251-257
59. Kimbauer R., Booy F., Cheng N., Lowy D., and Schiller J. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 89 (1992) 12180-12184
60. Koutsky L.A., Ault K.A., Wheeler C.M., et al., Proof of Principle Study Investigators. Randomised clincial trial of human papillomavirus type 16 vaccine. N Engl J Med 347 (2002) 1645-1651
61. Villa L., Costa R., Petta C., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95 (2006) 1459-1466
62. Wheeler C., Kjaer S., Sigurdsson K., et al. The impact of quadrivalent human papillomavirus (HPV; Types 6,11,16 and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 199 (2009) 936-944
63. Paavonen J., Naud P., Salmerón J., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374 (2009) 301-314
64. Michels K.B., and zur Hausen H. HPV vaccine for all. Lancet 374 (2009) 268-270
65. Muñoz N., Manalastas R., Pitisuttithum P., et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 373 (2009) 1949-1957
66. Harper D. Preliminary HPV vaccine results for women older than 25 years. Lancet 373 (2009) 1921-1922
67. Barnabas R., Laukkanen P., Koskela P., Kontula O., Lehtinen M., and Garnett G.P. Epidemiology of HPV16 and cervical cnacer in Finland and the potential impact of vaccination mathematical modelling analysis. PLoS Med 3 (2006) e138
68. Kim J., and Goldie S. Health and economic implications of HPV vaccination in the United States. N Engl J Med 359 (2008) 821-832
69. Jit M., Choi Y., and Edmunds W. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 337 (2008) a769
70. Naucler P., Ryd W., Törnberg S., et al. Human papillomavirus and papanicolaou tests to screen for cervical cancer. N Engl J Med 357 (2007) 1589-1597
71. Cuzick J., Arbyn M., Sankaranarayanan R., et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 265 (2008) K29-K41
72. Schiffman M., and Wacholder S. From India to the world-a better way to prevent cervical cancer. N Engl J Med 360 (2009) 1453-1455
73. Rothman S., and Rothman D. Marketing HPV vaccine-implications for adolescent ehalth and medical professionalism. JAMA 302 (2009) 781-786
74. Slade B., Leidel L., Vellozzi C., et al. Postlicensure safety surveillance for quadrivalent human papillomavirs recombinant vaccine. JAMA 302 (2009) 750-757
75. Haug C. The risks and benefits of HPV vaccination. JAMA 302 (2009) 795-796
76. Wall S., Scherf C., Morison L., et al. Cervical human papillomavirus infection and squamous intraepithelial lesions in rural Gambia, West Africa: viral sequence analysis and epidemiology. Br J Cancer 93 (2005) 1068-1076
77. Sankaranarayanan R., Nene B., Shastri S., et al. HPV screening for cervical cancer in rural India. N Engl J Med 360 (2009) 1385-1394
78. Doll R. Prospects for prevention. BMJ 286 (1983) 445-453
79. Daar A., Singer P., Persad D., et al. Grand challenges in chronic non-communicable diseases. Nature 450 (2007) 494-496
80. Daar A., Nabel E., Pramming S., et al. The global alliance for chronic diseases. Science 324 (2009) 1642